U.S. markets open in 3 hours 36 minutes
  • S&P Futures

    4,405.25
    -27.75 (-0.63%)
     
  • Dow Futures

    34,646.00
    -97.00 (-0.28%)
     
  • Nasdaq Futures

    15,007.00
    -187.75 (-1.24%)
     
  • Russell 2000 Futures

    2,271.80
    -5.20 (-0.23%)
     
  • Crude Oil

    76.29
    +0.84 (+1.11%)
     
  • Gold

    1,739.20
    -12.80 (-0.73%)
     
  • Silver

    22.33
    -0.36 (-1.60%)
     
  • EUR/USD

    1.1680
    -0.0022 (-0.19%)
     
  • 10-Yr Bond

    1.4840
    0.0000 (0.00%)
     
  • Vix

    20.59
    +2.84 (+16.00%)
     
  • GBP/USD

    1.3645
    -0.0060 (-0.44%)
     
  • USD/JPY

    111.3440
    +0.3660 (+0.33%)
     
  • BTC-USD

    42,029.30
    -1,578.35 (-3.62%)
     
  • CMC Crypto 200

    1,042.97
    -58.55 (-5.32%)
     
  • FTSE 100

    7,034.54
    -28.86 (-0.41%)
     
  • Nikkei 225

    30,183.96
    -56.10 (-0.19%)
     

Calliditas Therapeutics Stock Falls As FDA Pushes Nefecon PDUFA Goal Date To December

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • The FDA has extended the PDUFA goal date for Calliditas Therapeutics AB's (NASDAQ: CALT) application seeking accelerated approval for Nefecon.

  • Nefecon is an oral formulation targeting down-regulation of IgA1 to treat primary IgA Nephropathy (IgAN).

  • The new goal date is December 15 compared to the previous September 15.

  • The FDA has requested further analyses of the NeflgArd trial data, which the company has provided to the FDA.

  • The amendment mainly provides additional eGFR and other related analyses to support further the proteinuria data provided in the application submission.

  • In March, Calliditas filed for FDA approval using the Accelerated Approval Program.

  • Related Content: Calliditas Therapeutics Files US Application For Nefecon In Kidney Disease.

  • In April, the Nefecon application was granted priority review status from the FDA.

  • In May, Calliditas filed a Nefecon application to European Medicines Agency.

  • Related content: Benzinga's Full FDA Calendar.

  • Price Action: CALT stock is down 8.62% at $22.37 during the premarket session on the last check Wednesday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.